Historical Context & Motivation
The discovery that DNA is not an inert, immutable molecule but rather a structure under constant assault from both endogenous and exogenous agents fundamentally reshaped our understanding of molecular biology. Estimates suggest that each human cell sustains on the order of 10,000 to 100,000 DNA lesions per day, arising from hydrolysis, oxidation, alkylation, and replication errors. Without robust repair systems, genomes would rapidly degrade, leading to mutagenesis, cell death, and organismal lethality. Early observations of photoreactivation in bacteria exposed to ultraviolet (UV) light hinted that cells possess enzymatic machinery dedicated to restoring DNA integrity. Over the subsequent decades, a rich tapestry of repair pathways was uncovered, each tailored to specific classes of damage and operating through distinct biochemical strategies.
These milestones collectively frame the central question that DNA repair biology seeks to answer: how do cells detect, identify, and faithfully restore damaged or incorrectly paired nucleotides to maintain genomic stability? Understanding these pathways is not merely an academic exercise—deficiencies in DNA repair underlie numerous cancers, aging phenotypes, and neurological diseases, and they serve as therapeutic targets in modern oncology.
Core Principles of DNA Repair
Despite the diversity of DNA repair pathways, several unifying principles govern how cells maintain genomic integrity. These core ideas provide the conceptual framework for understanding each specific mechanism in subsequent sections. The fidelity of the repair process itself is paramount, because an imprecise fix can be as mutagenic as the original lesion, or worse—it can generate chromosomal rearrangements that drive malignant transformation.
Damage Recognition
Strand Discrimination
Excise-Resynthesize-Ligate Paradigm
Redundancy & Pathway Choice
Signaling & Coordination
Overview of Major DNA Repair Pathways
The diagram below provides a comprehensive overview of the five major DNA repair pathways and the types of DNA damage each addresses. Each pathway is color-coded and positioned around the central DNA helix, which represents the shared substrate. Arrows indicate the flow from damage type to repair pathway, illustrating the principle that specific lesions are channeled to the pathway best suited for their correction.
As shown in the diagram, the left side of the figure groups pathways that address single-strand damage—BER for chemically altered individual bases, NER for bulky adducts that distort the helix, and MMR for misincorporated bases or small insertion–deletion loops. The right side illustrates the two primary pathways for double-strand break repair: homologous recombination, which requires a sister chromatid as a template and is therefore restricted to S and G₂ phases, and non-homologous end joining, which operates throughout the cell cycle but is inherently error-prone because it does not use a homologous template. The key enzymes listed in each box will be discussed in mechanistic detail in the following sections.
Mechanistic Details of Repair Pathways
Base Excision Repair (BER)
Base excision repair is the primary pathway for correcting small, non-helix-distorting base lesions such as 8-oxoguanine (a product of oxidative damage), uracil arising from cytosine deamination, and 3-methyladenine from alkylation. The pathway initiates when a lesion-specific DNA glycosylase recognizes and flips the damaged base out of the double helix into the enzyme's active site, where it cleaves the N-glycosidic bond between the base and the deoxyribose sugar, generating an apurinic/apyrimidinic (AP) site. AP endonuclease 1 (APE1) then incises the phosphodiester backbone 5ʹ to the AP site, creating a single-strand break with a 3ʹ-hydroxyl and a 5ʹ-deoxyribose phosphate (dRP) residue.
In short-patch BER (the predominant sub-pathway), DNA polymerase β (Pol β) fills the single-nucleotide gap and simultaneously removes the 5ʹ-dRP residue via its lyase activity. DNA ligase III, in complex with XRCC1, then seals the nick. In long-patch BER, Pol δ or Pol ε synthesizes a 2–10 nucleotide flap that is cleaved by flap endonuclease 1 (FEN1), and DNA ligase I seals the remaining nick. The choice between short-patch and long-patch BER depends on the nature of the 5ʹ blocking group and the availability of ATP.
Nucleotide Excision Repair (NER)
Nucleotide excision repair removes bulky, helix-distorting lesions, most notably UV-induced cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts, as well as chemical adducts formed by cisplatin and benzo[a]pyrene. NER operates via two sub-pathways that differ in damage recognition but converge on a shared excision mechanism. Global genome NER (GG-NER) scans the entire genome using the XPC–RAD23B complex as the primary sensor, which detects thermodynamic destabilization of the duplex rather than the lesion itself. Transcription-coupled NER (TC-NER) is triggered when RNA polymerase II stalls at a lesion on the template strand, recruiting CSA and CSB proteins to initiate repair.
Following damage verification by TFIIH (through its XPB and XPD helicase subunits), the damaged strand is incised on both sides of the lesion: XPG makes the 3ʹ incision and ERCC1–XPF makes the 5ʹ incision, excising a 24–32 nucleotide oligomer containing the lesion. Replicative polymerases (Pol δ or Pol ε) fill the gap using the undamaged strand as a template, and DNA ligase I or III completes the repair.
Mismatch Repair (MMR)
Mismatch repair corrects base–base mismatches and small insertion–deletion loops that escape the proofreading activity of replicative polymerases. In eukaryotes, the MutSα heterodimer (MSH2–MSH6) recognizes single-base mismatches and 1–2 nucleotide indels, while MutSβ (MSH2–MSH3) preferentially recognizes larger insertion–deletion loops. Upon mismatch binding, MutSα undergoes an ATP-dependent conformational change and recruits MutLα (MLH1–PMS2), which possesses a latent endonuclease activity activated by PCNA loading and RFC. MutLα incises the discontinuous (newly synthesized) strand, and exonuclease 1 (Exo1) degrades the error-containing segment. Pol δ resynthesizes the correct sequence, and DNA ligase I seals the nick.
Double-Strand Break Repair: HR and NHEJ
Double-strand breaks (DSBs) are the most cytotoxic form of DNA damage because both strands of the duplex are severed, eliminating the intact complementary strand that other pathways rely upon as a template. Cells repair DSBs primarily through two competing pathways. Homologous recombination (HR) is a high-fidelity pathway that uses the sister chromatid as a template and is therefore active predominantly during S and G₂ phases. The MRN complex (MRE11–RAD50–NBS1) initiates 5ʹ→3ʹ end resection, generating long 3ʹ single-stranded DNA overhangs. RPA coats the ssDNA to prevent secondary structure formation, and then the mediator protein BRCA2 loads RAD51 recombinase onto the ssDNA, displacing RPA and forming a nucleoprotein filament that invades the homologous duplex. After strand invasion, DNA synthesis extends the invading strand, and the repair is completed through resolution or dissolution of Holliday junction intermediates.
Non-homologous end joining (NHEJ) operates throughout the cell cycle and is the predominant DSB repair pathway in G₁, when no sister chromatid is available. The Ku70/Ku80 heterodimer rapidly binds broken DNA ends, recruits DNA-PKcs (DNA-dependent protein kinase catalytic subunit), and tethers the two ends together. End-processing enzymes such as Artemis trim incompatible overhangs, and the XRCC4–DNA ligase IV–XLF complex ligates the ends. Because NHEJ does not use a homologous template, it is inherently error-prone, often introducing small insertions or deletions at the junction. A more mutagenic alternative pathway, alternative end joining (alt-EJ / MMEJ), uses microhomologies of 5–25 nucleotides flanking the break to align ends before ligation, frequently causing larger deletions.
Damage Types and Pathway Classification
Matching the correct repair pathway to a given lesion is a central concept in understanding DNA repair biology. The table below categorizes common types of DNA damage by their source, chemical nature, and the primary repair pathway responsible for their correction. Note that many lesions can be addressed by more than one pathway, reflecting the redundancy that ensures genomic stability.
| Damage Type | Source / Agent | Chemical Nature | Primary Repair Pathway |
|---|---|---|---|
| 8-oxoguanine | Reactive oxygen species (ROS) | Oxidized base, can mispair with A | BER (OGG1 glycosylase) |
| Uracil in DNA | Spontaneous cytosine deamination | Non-native base; U:G mismatch | BER (UNG glycosylase) |
| Cyclobutane pyrimidine dimer | UV-B radiation (254–320 nm) | Covalent bond between adjacent pyrimidines | NER (GG-NER or TC-NER) |
| Benzo[a]pyrene-dG adduct | Tobacco smoke, grilled meats | Bulky covalent adduct distorting helix | NER (GG-NER) |
| G:T mismatch | Replication error (Pol slippage) | Non-Watson-Crick base pair | MMR (MutSα) |
| Insertion/deletion loop | Polymerase slippage at repeats | Extra or missing nucleotides in one strand | MMR (MutSα or MutSβ) |
| Double-strand break | Ionizing radiation, replication fork collapse | Both strands severed | HR (S/G₂) or NHEJ (G₁) |
| Interstrand crosslink | Cisplatin, mitomycin C, nitrogen mustards | Covalent link between complementary strands | Fanconi anemia pathway + HR + NER |
Worked Example: Tracking Mutation Rate in MMR-Deficient Cells
While DNA repair is fundamentally a biochemical process, quantitative reasoning allows us to appreciate the functional significance of each pathway. The following worked example demonstrates how loss of mismatch repair elevates the mutation rate and can be detected experimentally through fluctuation assays or microsatellite instability analysis.
Comparing Repair Pathways: Fidelity, Speed, and Context
Each DNA repair pathway occupies a distinct niche defined by the type of damage it corrects, the fidelity of the repair, its speed of action, and the cell cycle phases in which it operates. The table below provides a side-by-side comparison that highlights the strengths and limitations of each major pathway, enabling students to predict which repair strategy a cell would deploy given a particular lesion and cellular context.
| Feature | BER | NER | MMR | HR | NHEJ |
|---|---|---|---|---|---|
| Lesion type | Small base modifications | Bulky, helix-distorting adducts | Mismatches, indels | Double-strand breaks | Double-strand breaks |
| Patch size | 1 nt (short) or 2–10 nt (long) | 24–32 nt | Up to ~1 kb | Variable (gene conversion tract) | 0–5 nt processing |
| Fidelity | High | High | High | High | Low (error-prone) |
| Speed | Fast (minutes) | Moderate (hours) | Coupled to replication | Slow (hours) | Fast (minutes) |
| Cell cycle | All phases | All phases (TC-NER needs transcription) | S phase (post-replication) | S/G₂ only | All phases (predominant in G₁) |
| Template required? | Complementary strand | Complementary strand | Complementary strand | Sister chromatid | None |
| Disease link | MUTYH polyposis | Xeroderma pigmentosum, Cockayne syndrome | Lynch syndrome | BRCA1/2 breast/ovarian cancer | LIG4 syndrome, SCID |
Connections to Advanced Topics: Synthetic Lethality & Therapy
The study of DNA repair mechanisms has yielded transformative advances in cancer therapy, particularly through the concept of synthetic lethality. Two genes are synthetically lethal when loss of either alone is viable, but simultaneous loss of both is lethal. In the context of DNA repair, tumor cells with a pre-existing deficiency in one repair pathway (e.g., HR due to BRCA1/2 mutation) become critically dependent on a backup pathway (e.g., BER/single-strand break repair involving PARP1). Pharmacological inhibition of this backup pathway with PARP inhibitors (olaparib, niraparib, rucaparib) selectively kills HR-deficient cancer cells while sparing normal cells that have functional HR. This therapeutic strategy, validated in clinical trials for BRCA-mutated breast and ovarian cancers, represents a paradigm shift from cytotoxic chemotherapy toward genotype-targeted therapy.
| Concept | Undergraduate Level (This Lesson) | Advanced / Graduate Level |
|---|---|---|
| Pathway regulation | Cell cycle-dependent choice between HR and NHEJ | CDK-dependent phosphorylation of CtIP, 53BP1/BRCA1 antagonism, chromatin remodeling at DSBs |
| Checkpoint signaling | ATM/ATR activate Chk1/Chk2 → cell cycle arrest | γH2AX spreading, MDC1 scaffolding, RNF8/RNF168 ubiquitin signaling, liquid–liquid phase separation at damage sites |
| Translesion synthesis | DNA damage tolerance via error-prone polymerases (Pol η, Pol ζ) | PCNA monoubiquitination by RAD6/RAD18, polymerase switching mechanisms, template switching vs. TLS |
| Therapeutic targeting | PARP inhibitors exploit HR deficiency (synthetic lethality) | ATR inhibitors, DNA-PKcs inhibitors, POLQ inhibitors, radioligand-conjugated DNA damagers |
| Epigenetic dimensions | MLH1 promoter methylation silences MMR in sporadic cancers | Histone modifications (H3K36me3 recruits MutSα), R-loops as sources of replication stress, transcription-replication conflicts |
As you advance in your studies, you will encounter increasingly sophisticated regulatory layers governing DNA repair, including post-translational modifications (ubiquitylation, SUMOylation, PARylation), chromatin dynamics, and the interplay between repair pathways and replication fork stability. The foundational knowledge of the five major repair pathways presented in this lesson provides the essential framework upon which these advanced concepts are built.
Practice Problems
DNA Repair Mechanisms — Summary
DNA is constantly damaged by endogenous and exogenous agents, but cells maintain genomic integrity through five major repair pathways. Base excision repair (BER) corrects small, non-helix-distorting lesions (oxidized bases, deaminations) via a glycosylase → APE1 → Pol β → ligase cascade. Nucleotide excision repair (NER) removes bulky, helix-distorting adducts (UV dimers, chemical crosslinks) by excising a 24–32 nucleotide oligomer, with sub-pathways for global genome surveillance (GG-NER) and transcription-coupled repair (TC-NER). Mismatch repair (MMR) corrects replication errors missed by polymerase proofreading, using the MutSα/MutLα system and strand-discrimination signals to ensure the newly synthesized strand is corrected. These three pathways share the excise-resynthesize-ligate paradigm and all rely on the intact complementary strand as a template.
Double-strand breaks, the most dangerous lesions, are repaired by homologous recombination (HR) in S/G₂ phase using the sister chromatid as a template (high fidelity, requiring BRCA1/2 and RAD51) or by non-homologous end joining (NHEJ) throughout the cell cycle (fast but error-prone, using Ku70/80 and DNA ligase IV). The DNA damage response (DDR) coordinates repair with cell cycle checkpoints via ATM/ATR kinases, ensuring repair is completed before replication or division. Deficiencies in these pathways cause cancer predisposition syndromes (xeroderma pigmentosum, Lynch syndrome, BRCA-associated cancers) and are exploited therapeutically through synthetic lethality strategies such as PARP inhibitor treatment of HR-deficient tumors.